Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsCreative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsCreative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
HighlightsWith deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
HighlightsGet a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
HighlightsLead molecules selected solely against human targets often lose binding activity when tested in cynomolgus monkeys, mice, or dogs, resulting in unreliable toxicology evaluations and serious regulatory delays.
Comprehensive cross-species reactivity data (human, cynomolgus, mouse, rat, rabbit, canine, etc.) is the critical decision-making foundation for selecting suitable animal models, de-risking preclinical development, and satisfying GLP and health authority expectations.
Pharmacological activity data requirement in at least two relevant species.
Both rodent and non-rodent toxicology data are expected.
Non-conserved epitopes on human targets frequently lead to complete failure in animal models.
Lead candidates lack binding in animal models: missing efficacy/toxicity data.
Wrong model selection causes repeated studies, budget drain, and delayed timelines.
Programs stall or terminate due to inability to meet filing requirements.
Requires individual expression and purification of soluble target proteins for each species.
Lengthy timelines, batch variability, and extremely challenging for multi-pass transmembrane targets.
Conformation-sensitive epitopes often inactivated during purification.
In therapeutic antibody development, candidate attrition during preclinical in vivo studies due to poor species cross-reactivity is a notoriously costly and time-consuming bottleneck. Utilizing our robust Yeast Surface Display Platform, we offer an end-to-end antibody discovery and engineering service specifically optimized for developing leads with broad cross-species reactivity.
By bypassing the tedious and often problematic expression of purified soluble target proteins from multiple species, our platform performs parallel, high-throughput screening directly under native eukaryotic folding conditions. We deliver fully validated antibody candidates equipped with comprehensive cross-reactivity matrices, quantitative binding heatmaps, and data-driven animal model recommendations.
for free technical support
Boasting solid stability and high transformation efficiency, Creative Biolabs' yeast display platform supports eukaryotic protein folding and post-translational modification. It is fully integrated with high-sensitivity flow cytometry for quantitative screening. The platform has been validated across hundreds of antibodies and protein engineering campaigns, including soluble targets as well as multi-pass transmembrane proteins and other challenging antigens. We deliver a complete closed-loop from display construction to data interpretation, ensuring that cross-reactivity results directly inform animal model selection.
Dive deeper into our platform capabilities: Yeast Display Technology Platform Main Page
Creative Biolabs offers complete yeast display systems to support varied research and therapeutic programs. With proficiency across multiple antibody modalities, we provide customized professional solutions for all project requirements. Click the link below to browse our complete service portfolio:
High-diversity, high-fidelity custom libraries.
FACS-based high-throughput precise screening.
From immunization/library to lead candidates in one stop.
Affinity maturation, stability enhancement, directed evolution.
Linear/cyclic peptide ligand discovery and epitope mapping.
Dual-platform synergy for efficient fully human lead discovery.
and receive a customized plan tailored to your specific target.
Creative Biolabs maintains a bank of high-quality recombinant antigens and offers rapid custom preparation. Obtain a clear species-reactivity map before entering animal studies, directly guiding model selection and engineering strategies.
Provide candidate sequences (or libraries) and target antigen details. Upon signing the NDA, we collaborative define the target species panel (e.g., human, mouse, rat, non-human primates).
Candidate antibody genes are cloned into proprietary yeast surface display vectors, followed by culture optimization to ensure efficient, high-density surface presentation.
Parallel engagement with multi-species targets under native eukaryotic folding conditions. This supports diverse antigen formats, including cells, membrane preparations, or micro-scale antigens, eliminating the need for tedious bulk protein purification.
Simultaneous multi-channel binding detection via Flow Cytometry. We output precise mean fluorescence intensity (MFI) and quantitative binding curves, delivering deep affinity metrics rather than simple positive/negative calls.
Next-generation sequencing (NGS) and single-clone validation are integrated to precisely link unique sequence identities with their cross-species binding profiles.
Receive a comprehensive data package including quantitative binding heatmaps, cross-reactivity scores, candidate rankings, and data-driven preclinical animal model recommendations.
Our team has constructed and screened dozens of high-quality yeast display libraries, proficient with antibody fragments, full-length proteins, and diverse formats
We maintain rigorously validated recombinant antigens for human, cynomolgus, mouse, rat, rabbit, canine, and more. Rapid custom antigen generation for exotic species is available — eliminating your in-house expression burden.
Flow cytometry-derived mean fluorescence intensity and binding percentages are transformed into cross-reactivity matrix heatmaps, enabling direct candidate comparison — no ambiguous qualitative readouts.
Beyond raw binding data, we provide candidate ranking and actionable animal model recommendations aligned with your pharmacology/toxicology strategy and regulatory pathway.
Demonstrated success in cross-reactivity evaluation for GPCRs, multi-pass transmembrane proteins, and pH-sensitive antibodies, underscoring our technical maturity.
Single point of contact from experimental design through report delivery, with regular progress updates and transparent communication.
A wide range of mature yeast display library screening services are well-received by clients, with core offerings as follows:
. Empower your research with professional support and explore more possibilities of yeast display.
Creative Biolabs giving every candidate a clear species reactivity map.
Have further questions? , who provide 24-hour online support to address all your inquiries.
All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.
